Cerenome (PSTV) Interest Expenses (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Interest Expenses of $17000.0 for Q1 2026, down 96.9% year-over-year from $548000.0 in Q1 2025, and up 103.51% quarter-over-quarter from -$485000.0 in Q4 2025.
Cerenome (PSTV) Interest Expenses (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Interest Expenses for 17 consecutive years, with $17000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 96.9% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $227000.0 (down 69.97% YoY), while the FY2025 annual figure was $25.9 million, up 14.77% from the prior year.
- Interest Expenses rose to $17000.0 in Q1 2026 per PSTV's latest filing, from -$485000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.4 million in Q2 2023 and bottomed at -$485000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $177756.4 across 5 years, with a median of $123500.0 in 2023.
- On a YoY basis, Interest Expenses climbed as much as 1511.76% in 2025 and fell as far as 429.93% in 2025.
- Plus Therapeutics' Interest Expenses stood at $159000.0 in 2022, then jumped by 31.45% to $209000.0 in 2023, then declined by 29.67% to $147000.0 in 2024, then tumbled by 429.93% to -$485000.0 in 2025, then surged by 103.51% to $17000.0 in 2026.
- Business Quant data shows PSTV's Interest Expenses at $17000.0 in Q1 2026, -$485000.0 in Q4 2025, and $1103.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | -485,000.00 |
| Dec 31, 2025 | -485,000.00 |
| Sep 30, 2025 | 1,103.00 |
| Sep 30, 2025 | 1,103.00 |
| Mar 31, 2025 | 548,000.00 |
| Mar 31, 2025 | 548,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Dec 31, 2024 | 147,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Sep 30, 2024 | 64,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 209,000.00 |
| Dec 31, 2023 | 209,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Sep 30, 2023 | 87,000.00 |